B. Riley initiated coverage on shares of GT Biopharma (OTCMKTS:GTBP) in a research note released on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $21.00 target price on the stock.
Separately, Roth Capital began coverage on shares of GT Biopharma in a report on Tuesday, March 23rd. They issued a buy rating and a $25.00 price target for the company.
OTCMKTS:GTBP opened at $9.90 on Monday. GT Biopharma has a 12-month low of $2.04 and a 12-month high of $13.09. The firm has a 50-day moving average price of $7.38 and a 200 day moving average price of $2.57.
About GT Biopharma
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors.
Featured Article: What is the Book Value of a Share?
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.